Abstract: A number of anti-angiogenic strategies connected with the VEGF signalling pathway are used in current clinical treatment or trial phase, but they either cause adverse effects or are not specific. Various strategies were aimed at identifying peptides inhibiting the VEGF-A165/NRP-1 interaction. A well-known antiangiogenic peptide is the heptapeptide termed “A7R” having the amino acid sequence ATWLPPR, for which various derivatives have been synthesized, which include peptides having the general sequence Lys(hArg)-AA2-AA3-Arg. However, the ability of the known peptides to inhibit the VEGF-A165/NRP-1 interaction was too low for their use as candidate drugs for inhibiting angiogenesis in subjects in need thereof. The present inventors have now conceived a family of novel peptide-like compounds having a nanomolar affinity for NRP-1, which are thus endowed with a powerful capacity to inhibit the VEGF-A165/NRP-1 interaction.

Abstract: The invention pertains to novel hybrid peptidomimetics, pharmaceutical composition comprising thereof and use thereof in the treatment of neuropathic pain. The hybrid peptidomimetics according to the invention are comprised of two components: an opioid receptor agonist (OP) and a MC4 receptor antagonist, connected by a linker. The compounds of such a structure will allow to activate opioid receptors with simultaneous blocking of melanocortin type 4 receptors (MC4), which results in enhancing efficiency of the opioid therapy in neuropathic pain.

Abstract: The present invention relates to novel cyclic peptidomimetics, pharmaceutical compositions containing them and their use in the treatment of diseases associated with angiogenesis especially tumors and chronic inflammation in psoriasis, diabetes, degenerative diseases of the eye (ARMD), nephropathy and neuropathy.

Abstract: The invention pertains to novel hybrid peptidomimetics, pharmaceutical composition comprising thereof and use thereof in the treatment of neuropathic pain. The hybrid peptidomimetics according to the invention are comprised of two components: an opioid receptor agonist (OP) and a MC4 receptor antagonist, connected by a linker. The compounds of such a structure will allow to activate opioid receptors with simultaneous blocking of melanocortin type 4 receptors (MC4), which results in enhancing efficiency of the opioid therapy in neuropathic pain.

Abstract: Peptidomimetic analogs suitable for use in cancer therapy, or as antagonists of opioid drugs, and suitable application of the compounds are disclosed. The described compounds display cytostatic and cytotoxic effects toward intestinal cancer cells, and pancreatic cancer cells, display affinity to ? and ? receptors, and act as antagonists of opioid drugs. Particularly, they are intended for administration to gastrointestinal system, in the form of tablets, infusions, injections, or implants, in therapy and supporting therapy of intestinal or pancreatic cancer, and in elimination of respiratory depression triggered by opioids, and to assure appropriate intestine peristalsis during an opioid therapy.

Abstract: The present invention relates to novel cyclic peptidomimetics, pharmaceutical compositions containing them and their use in the treatment of diseases associated with angiogenesis especially tumors and chronic inflammation in psoriasis, diabetes, degenerative diseases of the eye (ARMD), nephropathy and neuropathy.

Abstract: We disclose novel peptidomimetics with antiangiogenic activity and their uses, particularly in the treatment of neoplasms and chronic inflammation (in particular of: rheumatoid arthritis, colitis), in eczema, diabetes, age-related macular degeneration (ARMD), nephropathy and neuropathy, in particular for use in the form of intravenous infusions or injections, or implants releasing the active ingredient.

Abstract: Inflammation caused by disease states such as rheumatism, gout, neurodegeneration and tumours result in the increased effectiveness of the opioid peptide biphalin or its analogues, due likely to the increased permeability of the “blood-brain barrier”, due to which it becomes possible to use the opioid peptide to produce a new analgesic for use during inflammation caused by rheumatism, gout, neurodegeneration, post-surgical or post-accidental trauma or tumours.

Abstract: Inflammation caused by disease states such as rheumatism, gout, neurodegeneration and tumours result in the increased effectiveness of the opioid peptide biphalin or its analogues, due likely to the increased permeability of the “blood-brain barrier”, due to which it becomes possible to use the opioid peptide to produce a new analgesic for use during inflammation caused by rheumatism, gout, neurodegeneration, post-surgical or post-accidental trauma or tumours.

Abstract: The present invention provides a novel chimeric peptide containing an opioid peptide moiety and a nociceptive peptide moiety for producing analgesia.

Abstract: The present invention provides a novel chimeric peptide containing an opioid peptide moiety and a nociceptive peptide moiety for producing analgesia

Abstract: The present invention provides a novel chimeric peptide containing an opioid peptide moiety and a nociceptive peptide moiety for producing analgesia.